Hyperoxaluria| A Drug Pipeline Analysis Report 2018| Technavio
Aug. 03, 2018
LONDON--(BUSINESS WIRE)--Aug 3, 2018--Technavio has announced their latest analysis report on drug pipeline for . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat hyperoxaluria.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180803005363/en/
Technavio has published a new report on the drug development pipeline for hyperoxaluria, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Hyperoxaluria: Market overview
Hyperoxaluria is a state of disordered metabolism characterized by an increased urinary excretion of oxalate. The daily oxalate excretion in healthy individuals ranges between 10 mg and 40 mg per 24 hours. Concentrations exceeding 40-45 mg per 24 hours are considered as clinical hyperoxaluria. Hyperoxaluria is of several types including primary hyperoxaluria, oxalosis, enteric hyperoxaluria, hyperoxaluria related to eating high-oxalate foods.
According to a senior market research analyst at Technavio, “The worldwide prevalence of primary hyperoxaluria is estimated to affect one in 58,000 individuals. One estimate places the prevalence of primary hyperoxaluria type I at 1-3 cases per 1,000,000 people in the general population, and the incidence at one case per 120,000 live births per year in Europe. Hyperoxaluria is uncommon, though it can be found in about 20% of individuals with kidney stones.”
Hyperoxaluria: Segmentation analysis
This pipeline analysis report segments the hyperoxaluria market based on therapies employed (monotherapy), RoA (oral and subcutaneous), therapeutic modality (enzyme, SiRNA, and biological), targets (oxalate, glycolate oxidase, LDHA gene, and hydroxyacid oxidase 1), MoA (oxalate degraders, reduces hepatic glycolate oxidase, silences the LDHA gene, and gene transfer), geographical segmentation (US, UK, Spain, Netherlands, Germany, France, Jordan, Israel and Belgium) and recruitment status (active, not recruiting, completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 50% of the molecules that are being investigated for the treatment of hyperoxaluria are enzymes.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180803005363/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/03/2018 11:17 AM/DISC: 08/03/2018 11:18 AM